Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor

H. WongGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USACorrespondence[email protected]

J.Z. ChenGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

B. ChouGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

J.S. HalladayGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

J.R. KennyGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

H. LaGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

J.C. Marsters JrGenentech, Inc., Exploratory Clinical Development, South San Francisco, CA, USA

E. PliseGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

P.J. RudewiczGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

K. RobargeGenentech, Inc., Medicinal Chemistry, South San Francisco, CA, USA

Y. ShinGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

S. WongGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

C. ZhangGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

S.C. KhojastehGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA 94080, USA

References